Mary C. Beckerle Sells 12,210 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Exelixis Price Performance

Exelixis stock opened at $35.07 on Thursday. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $37.59. The stock has a market capitalization of $9.82 billion, a PE ratio of 19.81, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. The business has a 50 day simple moving average of $34.16 and a 200-day simple moving average of $31.11.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Exelixis

Hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. boosted its stake in Exelixis by 308.1% during the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after purchasing an additional 3,001,204 shares during the last quarter. Norges Bank purchased a new position in Exelixis in the 4th quarter worth approximately $94,867,000. Caisse DE Depot ET Placement DU Quebec boosted its holdings in shares of Exelixis by 330.4% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock worth $82,730,000 after purchasing an additional 1,907,167 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Exelixis by 104.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock valued at $105,208,000 after purchasing an additional 1,613,482 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its position in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EXEL. Stephens restated an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. Barclays raised their price target on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Exelixis in a report on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a research note on Thursday, January 23rd. Finally, Guggenheim restated a “buy” rating and set a $42.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $37.24.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.